VSEE HEALTH (VSEE) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for VSEE HEALTH.

Research analysts covering VSEE HEALTH.

Recent press releases and 8-K filings for VSEE.

VSee Health, Inc. Designates Series B Convertible Preferred Stock

VSEE

Convertible Preferred Issuance

VSee Health, Inc. designated 2,000 shares of Series B Convertible Preferred Stock, effective December 5, 2025, each with a stated value of $1,000.
This Series B Preferred Stock ranks senior to Common Stock and junior securities, and on parity with Series A Preferred Stock, regarding dividends and liquidation.
Holders can convert each share into Common Stock at a conversion price of $0.65, provided that Investor Gross Proceeds from the sale of Investor Shares are less than $2.3 million.
A beneficial ownership limitation of 9.99% of outstanding Common Stock applies to conversions.
Any outstanding Series B Preferred Stock or Conversion Shares will be automatically canceled if Investor Gross Proceeds equal or exceed the Investor Amount of $2.132 million.

Dec 11, 2025, 10:30 PM

VSee Health, Inc. announces private placement of common stock and warrants

VSEE

VSee Health, Inc. (VSEE) entered into a securities purchase agreement on November 25, 2025, for a private placement with a single institutional and accredited investor.
The company agreed to sell 9,836,065 shares of common stock (or pre-funded warrants) and accompanying common warrants to purchase up to 19,672,130 shares of Common Stock.
The offering is expected to generate approximately $6 million in gross proceeds, with a purchase price of $0.61 per share (or Pre-Funded Warrant) and accompanying Warrants.
The warrants have an exercise price of $0.61 per share and will expire five years from their initial exercise date, which is contingent on stockholder approval.
The net proceeds from the offering are intended for working capital and general corporate purposes, with the closing anticipated around December 1, 2025.

Nov 26, 2025, 9:40 PM

VSee Health Enters Convertible Note Purchase Agreement

VSEE

Debt Issuance

New Projects/Investments

VSee Health, Inc. (VSEE) entered into a Convertible Note Purchase Agreement with M2B Funding Corp. on October 29, 2025.
Under the agreement, the investor purchased a convertible promissory note with an initial principal amount of $217,391 and 50,000 shares of common stock for an aggregate purchase price of $201,000.
The note accrues interest at 18% per annum, matures on October 29, 2026, and is convertible into common stock at $0.48 per share starting January 29, 2026.
The Company's obligations under the note are secured by a security interest on all of its assets, which is junior only to existing finance obligations with Ascent Partners Fund LLC and Dominion Capital LLC.
The investor also holds a right to purchase an additional convertible promissory note on the same terms for up to 12 months.

Nov 17, 2025, 9:31 PM

VSee Health, Inc. Enters into Exchange Agreement and $25 Million Equity Line of Credit

VSEE

Debt Issuance

New Projects/Investments

On November 13, 2025, VSee Health, Inc. entered into an exchange agreement with an accredited institutional investor to convert a promissory note with a current balance of $611,878.22 into 941,352 shares of the Company's common stock.
The Company also established a $25,000,000 Equity Line of Credit (ELOC) arrangement with an accredited institutional investor on November 13, 2025, which has a 36-month term and is terminable by the Company at any time.
Under the ELOC, the Company may sell common stock at a price based on the Volume-Weighted Average Price (VWAP), with the Regular Purchase Price being 96% (or 94% if below $1.00) of the lowest VWAP over ten trading days, and the Company may not sell more than 19.9% of its outstanding common stock.
The net proceeds from the ELOC will be utilized for working capital and general corporate purposes.

Nov 17, 2025, 12:50 PM

VSee Health, Inc. Announces Warrant Exchange Agreement

VSEE

VSee Health, Inc. entered into a warrant exchange agreement with an accredited institutional investor on October 29, 2025.
Under the agreement, the investor will exercise approximately 130,000 outstanding warrants for cash.
The investor will also exchange an additional 2,250,000 outstanding warrants for 2,175,000 shares of the Company's common stock.
The Company has agreed to a 10-day restriction following the agreement date on issuing common stock or equivalents, effecting reverse stock splits, or filing registration statements, subject to certain exemptions.

Oct 29, 2025, 11:01 AM

Get instant answers from SEC filings, earnings calls & more